Vyome Holdings, Inc — fact timeline

Vyome Holdings, Inc reported first quarter ended March 31, 2026 results: net income Net loss attributable to common shareholders for the quarter ended March 31, 2026, was approximately $963,000, or approx, EPS approximately $0.15 per basic and diluted share.

“Vyome Holdings, Inc. issued a press release announcing its financial results for its first fiscal quarter ended March 31, 2026.”

Vyome Holdings, Inc: Approved an amendment to decrease authorized common stock from 300,000,000 to 50,000,000 shares (effective 2026-04-24).

“On April 24, 2026, the Company filed the Certificate of Tenth Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effectuate the decrease in authorized shares.”

Vyome Holdings, Inc amended Notes Purchase and Exchange Agreement with Remus Capital Series B II, L.P. (effective 2026-02-25).

“☐ Item 1.01 Entry into a Material Definitive Agreement Notes Purchase and Exchange Agreement As previously reported, on December 17, 2025,”

Vyome Holdings, Inc entered into Notes Purchase and Exchange Agreement with Remus Capital Series B II, L.P. valued at aggregate principal amount of $5,765,000 (effective 2026-02-20).

“As of February 20, 2026, pursuant to the terms of the LOI, the Company entered into a Notes Purchase and Exchange Agreement (the “Agreement”) by and among LICH, LICH AI Inc. (the “Buyer”), a subsidiary of LICH, and Remus to effectuate the transactions contemplated by the LOI.”

Vyome Holdings, Inc engaged Kreit & Chiu CPA LLP as its auditor.

“Effective as of August 18, 2025 Kreit & Chiu CPA LLP (“Kreit & Chiu”) was appointed to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”

Vyome Holdings, Inc dismissed Haskell & White LLP as its auditor.

“On August 18, 2025, Haskell & White LLP (“Haskell”), was dismissed as the independent registered public accounting firm of the Company, formerly ReShape Lifesciences Inc.”

Vyome Holdings, Inc: Filed Certificate of Ninth Amendment to change corporate name to Vyome Holdings, Inc. and set board composition with six directors in three classes (effective 2025-08-15).

“a Certificate of Ninth Amendment (the “Certificate of Ninth Amendment”) with the Secretary of State of the State of Delaware to amend the Company’s Restated Certificate of Incorporation, as amended, to change its corporate name to Vyome Holdings, Inc. and set forth the Combined Company’s composition of board of directors which will be initially comprised of six directors and divided into three classes with staggered three-year terms”

Vyome Holdings, Inc: Filed Certificate of Eighth Amendment to effect 1-for-4 reverse stock split (effective 2025-08-15).

“on August 15, 2025 the Company filed a Certificate of Eighth Amendment (the “Certificate of Eighth Amendment”) with the Secretary of State of the State of Delaware to amend the Company’s Restated Certificate of Incorporation, as amended, and effected the Reverse Stock Split on August 15, 2025.”

Vyome Holdings, Inc completed a disposition involving Ninburgh Health International Limited for $2.25 million in cash (closed 2025-04-25).

“Asset Purchase Agreement, ReShape sold its assets (excluding cash) to Biorad, and Biorad assumed substantially all of ReShape’s liabilities, for an agreed upon purchase price of $2.25 million in cash, subject to adjustment based on ReShape’s actual accounts receivable and accounts payable at the closing, compared to such amounts as of March 31, 2024.”

Vyome Holdings, Inc completed an acquisition involving Vyome Therapeutics, Inc. (closed 2025-08-15).

“On August 15, 2025, Vyome Holdings, Inc. (f/k/a ReShape Lifesciences Inc.) (the “Company”) completed the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the “Merger Agreement”), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and Vyome Therapeutics, Inc. (“Vyome”).”

Vyome Holdings, Inc received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“May 28, 2025, ReShape Lifesciences Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that Nasdaq has determined to delist the Company’s securities from Nasdaq. On November 25, 2024, Nasdaq notified the Company that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b). However, Nasdaq granted the Company’s request for an extension until May 27, 2025 to comply with this requirement. Nasdaq has determined that”

Vyome Holdings, Inc: Filed Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2025-05-06).

“On May 6, 2025, ReShape Lifesciences Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse split of the Company’s outstanding common stock, $0.001 par value per share (the “Reverse Stock Split”).”

Gary Blackford resigned as Director at Vyome Holdings, Inc.

“Gary Blackford informed the Board of Directors (the “Board”) of ReShape Lifesciences Inc. (the “Company”) of his decision to resign from the Board and all related committees effective March 15, 2025.”

Vyome Holdings, Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 25, 2024, ReShape Lifesciences Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of the Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity for continued listing. As of September 30, 2024, the Company’s stockholders’ equity was $1,487,000. Under the Nasdaq Listing Rules the Company has 45 calendar days to submit a plan to reg”

Vyome Holdings, Inc engaged Haskell & White LLP as its auditor.

“with the prior approval of the Audit Committee, the Company engaged Haskell & White LLP (“Haskell & White”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 and related interim periods.”

Vyome Holdings, Inc dismissed RSM US LLP as its auditor.

“On April 8, 2024, ReShape Lifesciences Inc. (the “Company”), with the prior approval of the Audit Committee of the Board of Directors, dismissed RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm, effective immediately.”

Vyome Holdings, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 9, 2024, the Company received a written notice from the Nasdaq Staff that the Company has not regained compliance with the minimum $1.00 bid price requirement. However, the Nasdaq Staff has determined that the Company is eligible for an additional 180 calendar period, or until October 7, 2024, to regain compliance. If at any time during this period the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq Staff will provide the Company with a written confirmation of compliance and the matter will be closed. I”

Vyome Holdings, Inc reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $8.7 million. Guidance reaffirmed.

“Revenue totaled $8.7 million for the year ended December 31, 2023”

Vyome Holdings, Inc shareholders approved Ratification of appointment of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-02-23 meeting.

“Proposal 5 : The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, as set forth below. Votes For Votes Against Abstentions 6,988,147 ​ 1,127,305 ​ 236,602”

Vyome Holdings, Inc shareholders approved Advisory approval of named executive officer compensation at the 2024-02-23 meeting.

“Proposal 4 : The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 1,144,098 ​ 847,403 ​ 27,670 ​ 6,332,883”

Vyome Holdings, Inc shareholders approved Approval of issuance of shares underlying warrants to an investor pursuant to Inducement Offer in excess of 20% of outstanding common stock under Nasdaq Listing Rule 5635(d) at the 2024-02-23 meeting.

“Proposal 3 : The Company’s stockholders approved the issuance of shares of the Company’s common stock underlying warrants issued to an investor pursuant to that certain Inducement Offer to Exercise Common Stock Purchase Warrants, dated as of November 21, 2023, in an amount equal to 20% or more of the Company’s common stock outstanding before the issuance of such warrants upon the operation of anti-dilution provisions contained in such warrants, as required by and in accordance with Nasdaq Listing Rule 5635(d), as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 1,158,808 ​ 801,271 ​ 59,092 ​ 6,332,883”

Vyome Holdings, Inc shareholders approved Authorize Board to amend Restated Certificate of Incorporation to effect a reverse stock split at a ratio in the range of 1-for-10 to 1-for-60 at the 2024-02-23 meeting.

“Proposal 2 : The Company’s stockholders authorized the Company’s Board of Directors (the “Board”), in its discretion but in no event later than February 23, 2025, which is one year after the date of the Annual Meeting, to amend the Company’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, at a ratio in the range of 1-for-10 to 1-for-60, such ratio to be determined by the Board and included in a public announcement, as set forth below. Votes For Votes Against Abstentions 5,751,242 ​ 2,584,917 ​ 15,895”

Vyome Holdings, Inc shareholders approved Election of Dan W. Gladney and Lori McDougal as Class I directors at the 2024-02-23 meeting.

“Proposal 1 : The Company’s stockholders elected Dan W. Gladney and Lori McDougal as Class I directors to hold office until the 2026 annual meeting of stockholders or until his or her successor is elected and qualified, or, if sooner, until his or her death, resignation or removal, as set forth below. ​ ​ ​ Votes For Votes Withheld Broker Non-Votes ​ Dan W. Gladney ​ 1,387,535 ​ 631,636 ​ 6,332,883 ​ Lori McDougal ​ 1,511,604 ​ 507,567 ​ 6,332,883”

Vyome Holdings, Inc: Amended quorum requirement for stockholder meetings from majority to one-third of voting power (effective 2024-01-16).

“Article I, Section 1.5 of the Bylaws was amended to modify the quorum required for the transaction of business at a meeting of stockholders of the Company to provide that the presence, in person or by proxy, of holders of one-third (1/3rd) of the voting power of the shares of stock issued and outstanding and entitled to vote at the meeting will constitute a quorum for the transaction of business at such meeting”

Vyome Holdings, Inc received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 11, 2024, ReShape Lifesciences Inc. (the "Company") received a written notice from the Listing Qualifications department of The Nasdaq Stock Market stating that because the Company has not yet held an annual meeting of shareholders within 12 months of the end of the Company's 2022 fiscal year end, it no longer complies with Nasdaq Listing Rule 5620 (a) for continued listing on The Nasdaq Capital Market. The Company has until February 26, 2024, which is 45 days from the date of the notice, to submit a plan to regain compliance and, if Nasdaq accepts the plan, it may grant an exception o”

Vyome Holdings, Inc entered into warrant exercise agreement with an existing accredited investor valued at approximately $1.2 million (effective 2023-11-21).

“On November 21, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants”

Vyome Holdings, Inc reported financial results for three and nine months ended September 30, 2023.

“On November 8, 2023, ReShape Lifesciences Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023.”

Vyome Holdings, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 10, 2023, ReShape Lifesciences Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, the Company no”

Vyome Holdings, Inc entered into Securities Purchase Agreement with certain investors valued at approximately $2.8 million (effective 2023-09-29).

“On September 29, 2023, ReShape Lifesciences Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Investors")”

Vyome Holdings, Inc entered into License Agreement with Biorad Medysis Pvt. Ltd. valued at $200,000 in upfront payments (effective 2023-09-19).

“On September 19, 2023, ReShape Lifesciences Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Biorad Medysis Pvt. Ltd. (“Biorad”), pursuant to which the Company granted an exclusive license to Biorad to manufacture, commercialize and distribute the Company’s Obalon® Gastric Balloon System in the territory of India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives.”

Vyome Holdings, Inc reported financial results for the three and six months ended June 30, 2023.

“On August 7, 2023, ReShape Lifesciences Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.”

Vyome Holdings, Inc reported for the three months ended March 31, 2023 results: revenue $2.3 million.

“impact revenue for the remainder of 2023 and move ReShape closer to cash flow breakeven.” ​ First Quarter Ended March 31, 2023, Financial and Operating Results ​ Revenue totaled $2.3 million for the three months ended March 31, 2023, which represents a contraction of 6.3%, or $0.2 million compared to the same period in 2022. The primary reason for the decrease is a”

Vyome Holdings, Inc entered into Securities Purchase Agreement with a certain institutional investor valued at approximately $2.46 million (effective 2023-04-20).

“On April 20, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 291,395 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) pre-funded warrants to purchase an aggregate of 509,300 shares of Common Stock (the “Pre-funded Warrants”).”

Vyome Holdings, Inc entered into Lease with The Irvine Company LLC valued at $9,068 per month (effective 2023-03-13).

“On March 13, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a lease (the “Lease”) with The Irvine Company LLC, a Delaware limited liability company (the “Landlord”), whereby the Company agreed to lease approximately 5,038 square feet at 18 Technology Drive, Suite 110, Irvine, California 92618.”

Vyome Holdings, Inc entered into Underwriting Agreement with Maxim Group LLC valued at $8.00 per Unit (effective 2023-02-06).

“On February 6, 2023, ReShape Lifesciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC”

Vyome Holdings, Inc: Effected a 1-for-50 reverse stock split and increased authorized common stock from 100,000,000 to 300,000,000 shares (effective 2022-12-23).

“On December 21, 2022, ReShape Lifesciences Inc. (the "Company") filed a Certificate of Amendment (the "Certificate of Amendment") to its Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse split of the Company’s outstanding common stock, $0.001 par value per share (the "Reverse Stock Split"). The Reverse Stock Split became effective for trading purposes upon the commencement of trading on December 23, 2022, at which point the Company’s common stock began trading on a split adjusted basis on the Nasdaq Capital Market. As a result of the Reverse Stock Split, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split will be rounded up to the nearest whole share. As a result of the Reverse Stock Split, proportional adjustments will be ma”

Vyome Holdings, Inc shareholders approved Ratification of appointment of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2022 at the 2022-12-14 meeting.

“The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, as set forth below. Votes For Votes Against Abstentions 13,866,558 ​ 417,065 ​ 144,326”

Vyome Holdings, Inc shareholders approved Advisory vote on compensation of named executive officers at the 2022-12-14 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 4,054,583 ​ 1,837,687 ​ 55,150 ​ 8,480,529”

Vyome Holdings, Inc shareholders approved Amendment to Article IV, Section 1 of the Certificate of Incorporation to increase authorized common stock to 300,000,000 shares at the 2022-12-14 meeting.

“The Company’s stockholders approved an amendment to Article IV, Section 1 of the Certificate of Incorporation to increase the number of shares of common stock authorized for issuance to 300,000,000 shares, as set forth below. Votes For Votes Against Abstentions 72,167,316 ​ 17,231,487 ​ 29,146”

Vyome Holdings, Inc shareholders approved Authorization to amend Certificate of Incorporation to effect a reverse stock split at a ratio in the range of 1-for-30 to 1-for-100 at the 2022-12-14 meeting.

“The Company’s stockholders authorized the Board, in its discretion but in no event later than December 14, 2023, which is one year after the date of the Annual Meeting, to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, at a ratio in the range of 1-for-30 to 1-for-100, such ratio to be determined by the Board and included in a public announcement, as set forth below. Votes For Votes Against Abstentions 73,383,162 ​ 13,008,564 ​ 36,223”

Vyome Holdings, Inc shareholders approved Approval of the ReShape Lifesciences Inc. 2022 Equity Incentive Plan at the 2022-12-14 meeting.

“The Company’s stockholders approved the ReShape Lifesciences Inc. 2022 Equity Incentive Plan, as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 3,721,022 ​ 2,142,351 ​ 84,047 ​ 8,480,529”

Vyome Holdings, Inc shareholders approved Election of Paul F. Hickey as a Class III director at the 2022-12-14 meeting.

“The Company’s stockholders elected Paul F. Hickey as a Class III director to hold office until the 2025 annual meeting of stockholders or until his successor is elected and qualified, or, if sooner, until his death, resignation or removal, as set forth below. Votes For Votes Withheld Broker Non-Votes 5,366,444 ​ 580,976 ​ 8,480,529”

Vyome Holdings, Inc reported financial results for the three and nine months ended September 30, 2022.

“ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the third quarter ended September 30, 2022 and provided a corporate strategic update.”

Vyome Holdings, Inc amended Warrant Amendment Agreement.

“In connection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.”

Vyome Holdings, Inc entered into Securities Purchase Agreement valued at $750,000 (effective 2022-11-08).

“On November 8, 2022, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 2,392,524 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) 2,500 shares of the Company’s Series D Mirroring Preferred Stock, par value $0.001 per share and stated value of $0.001 per share (the “Preferred Stock”), and (iii) pre-funded warrants to purchase an aggregate of 492,091 shares of Common Stock (the “Pre-funded Warrants”).”

Dan W. Gladney was appointed as Executive Chair at Vyome Holdings, Inc.

“Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Executive Chair, supporting Mr. Hickey and the Company on strategic matters”

Thomas Stankovich was appointed as Interim President and Chief Executive Officer at Vyome Holdings, Inc.

“Thomas Stankovich, Chief Financial Officer of the Company, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the Company.”

Bart Bandy resigned as Member of the Board of Directors at Vyome Holdings, Inc.

“Mr. Bandy also resigned from the Board of Directors.”

Bart Bandy departed as President and Chief Executive Officer at Vyome Holdings, Inc.

“Mr. Hickey succeeds Bart Bandy, who has separated from the Company to pursue other opportunities.”

Paul F. Hickey was appointed as Member of the Board of Directors at Vyome Holdings, Inc.

“On July 27, 2022, ReShape Lifesciences Inc. (the “Company”) announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022.”